December 2, 2019
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaBookmarkGeorge Lundberg, MD
Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.